Selection of metastasis competent subclones in the tumour interior
Yue Zhao(Jackson Laboratory), Kevin Litchfield(Cancer Research UK), Steve Hazell(Royal Marsden NHS Foundation Trust), Ben Challacombe(Guy's and St Thomas' NHS Foundation Trust), Nicos Fotiadis(Royal Marsden NHS Foundation Trust), Lavinia Spain(Royal Marsden NHS Foundation Trust), Sergio A. Quezada(Memorial Sloan Kettering Cancer Center), Charles Swanton(The Francis Crick Institute), Peter Hill, Lisa Pickering(Royal Marsden Hospital), Mary Varia(Guy's and St Thomas' NHS Foundation Trust), Annika Fendler(The Francis Crick Institute), Jonathon Olsburgh(University of Basel), Emine Hatipoglu(Royal Marsden NHS Foundation Trust), Paul A. Bates(The Francis Crick Institute), Gordon Stamp(Royal Marsden Hospital), Catherine Horsfield(St Thomas' Hospital), Marcellus Augustine(The Francis Crick Institute), Samra Turajlic(Royal Marsden NHS Foundation Trust), José I. López(BioCruces Health research Institute), Karen Harrison‐Phipps, Andrew Rowan(Cancer Institute (WIA)), Alexander Polson(Guy's and St Thomas' NHS Foundation Trust), Antonia Toncheva(Cancer Research UK), Fiona Byrne(The Francis Crick Institute), Ashish Chandra(Guy's Hospital), Lewis Au(Royal Marsden NHS Foundation Trust), Xiao Fu, James Larkin(Trinity College Dublin), Erik Sahai(The Francis Crick Institute), Scott T.C. Shepherd(Royal Marsden NHS Foundation Trust), Hang Xu(Chinese Academy of Medical Sciences & Peking Union Medical College), David Nicol(Royal Stoke University Hospital), William Drake, Sarah Rudman(Guy's and St Thomas' NHS Foundation Trust), Hema Verma, Archana Fernando(Guy's and St Thomas' NHS Foundation Trust), Andrew Furness(Royal Marsden NHS Foundation Trust), Simon Chowdhury(Sarah Cannon Research Institute), Stuart Horswell(The Francis Crick Institute), Tim O’Brien(St Thomas' Hospital), Teresa Marafioti(Cancer Research UK)
Cited by 102
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
A framework for advancing our understanding of cancer-associated fibroblasts
|Nature reviews. Cancer|2020|3.7k
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2019|3.7k